167 related articles for article (PubMed ID: 24893616)
21. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
[TBL] [Abstract][Full Text] [Related]
22. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
Cermák J; Michalová K; Brezinová J; Zemanová Z
Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
[TBL] [Abstract][Full Text] [Related]
23. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Kulasekararaj AG; Smith AE; Mian SA; Mohamedali AM; Krishnamurthy P; Lea NC; Gäken J; Pennaneach C; Ireland R; Czepulkowski B; Pomplun S; Marsh JC; Mufti GJ
Br J Haematol; 2013 Mar; 160(5):660-72. PubMed ID: 23297687
[TBL] [Abstract][Full Text] [Related]
24. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Jädersten M; Saft L; Pellagatti A; Göhring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
Haematologica; 2009 Dec; 94(12):1762-6. PubMed ID: 19797731
[TBL] [Abstract][Full Text] [Related]
25. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities.
Gurney M; Patnaik MM; Hanson CA; Litzow MR; Al-Kali A; Ketterling RP; Tefferi A; Gangat N
Br J Haematol; 2017 Jul; 178(1):57-60. PubMed ID: 28419466
[TBL] [Abstract][Full Text] [Related]
26. Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1.
Rouhigharabaei L; Finalet Ferreiro J; Tousseyn T; van der Krogt JA; Put N; Haralambieva E; Graux C; Maes B; Vicente C; Vandenberghe P; Cools J; Wlodarska I
PLoS One; 2014; 9(1):e85851. PubMed ID: 24416450
[TBL] [Abstract][Full Text] [Related]
27. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
[TBL] [Abstract][Full Text] [Related]
28. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
Jaju RJ; Jones M; Boultwood J; Kelly S; Mason DY; Wainscoat JS; Kearney L
Genes Chromosomes Cancer; 2000 Nov; 29(3):276-80. PubMed ID: 10992302
[TBL] [Abstract][Full Text] [Related]
29. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes.
Raynaud SD; Baens M; Grosgeorge J; Rodgers K; Reid CD; Dainton M; Dyer M; Fuzibet JG; Gratecos N; Taillan B; Ayraud N; Marynen P
Blood; 1996 Jul; 88(2):682-9. PubMed ID: 8695816
[TBL] [Abstract][Full Text] [Related]
30. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
31. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
32. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
[TBL] [Abstract][Full Text] [Related]
33. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
J Clin Oncol; 2011 May; 29(15):1971-9. PubMed ID: 21519010
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic abnormalities in myelodysplastic syndrome: an overview.
Kawankar N; Vundinti BR
Hematology; 2011 May; 16(3):131-8. PubMed ID: 21669051
[TBL] [Abstract][Full Text] [Related]
35. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
[TBL] [Abstract][Full Text] [Related]
36. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
[TBL] [Abstract][Full Text] [Related]
37. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
38. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
39. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.
Lezon-Geyda K; Najfeld V; Johnson EM
Leukemia; 2001 Jun; 15(6):954-62. PubMed ID: 11417483
[TBL] [Abstract][Full Text] [Related]
40. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Bidet A; Dulucq S; Smol T; Marceau-Renaut A; Morisset S; Coiteux V; Noël-Walter MP; Nicolini FE; Tigaud I; Luquet I; Struski S; Gaillard B; Penther D; Tondeur S; Nadal N; Hermet E; Véronèse L; Réa D; Gervais C; Theisen O; Terré C; Cony-Makhoul P; Lefebvre C; Gaillard JB; Radford I; Vervaeke AL; Barin C; Chapiro E; Nguyen-Khac F; Etienne G; Preudhomme C; Mahon FX; Roche-Lestienne C;
Haematologica; 2019 Jun; 104(6):1150-1155. PubMed ID: 30573507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]